Kailera Therapeutics (NASDAQ:KLRA) Announces Earnings Results

Kailera Therapeutics (NASDAQ:KLRA) released its earnings results on Wednesday. The company reported ($1.09) EPS for the quarter, FiscalAI reports.

Kailera Therapeutics Trading Down 1.5%

Kailera Therapeutics stock traded down $0.28 during midday trading on Wednesday, reaching $18.59. The company’s stock had a trading volume of 246,466 shares, compared to its average volume of 712,311. The stock has a market cap of $2.41 billion and a P/E ratio of -0.01. The stock’s 50-day moving average is $19.60. Kailera Therapeutics has a fifty-two week low of $16.39 and a fifty-two week high of $28.23.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KLRA. TD Cowen initiated coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $48.00 target price on the stock. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. Evercore assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating on the stock. Finally, Leerink Partners assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.